Slide 1: AFT Pharmaceuticals Investor Presentation
AFT PHARMACEUTICALS Investor Presentation May 2017 Investor Presentation May 2017
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: Summary of AFT Business
SUMMARY OF AFT BUSINESS Established Business [1997] and growing AU & NZ Significant further potential growth in AU • - Newly launched and existing OTCs • - Maxigesic from Codeine switch The most significant growth opportunity: Growing Key Innovative Products outside ANZ via Distributors & Licensees.
Slide 4: Current Highlights
CURRENT HIGHLIGHTS countries that Maxigesic is licensed in 112 Further countries to license [around 20] 8 countries that Maxigesic is launched and sold in 12 number of clinical studies AFT will have running in FY2017 Maxigesic =5; Maxiclear = 1, Pascomer = 1; NasoSURF = 5 $70.8m total income for FY2
Slide 5: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2000 – FY2017 80 70 Operating revenue (NZ$m) 10 year CAGR: 15% 60 50 40 30 20 10 - FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY2016 Operating revenue by region FY2017 Operating revenue by region Southeast Asia Rest of
Slide 6: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2015 – FY2017 NZ$000's year ended March 2017 2015 % of total 2016 % of total 2017 % of total Australia 26,324 46.8% 31,224 48.8% 37,063 53.6% YoY growth 18.6% 18.7% New Zealand 29,398 52.3% 31,135 48.6% 29,167 42.1%
Slide 7: Financial Performance – Summary P&L
FINANCIAL PERFORMANCE – SUMMARY P&L NZ#039;000's year ended 31 March 2017 % of 2016 % of revenue revenue Revenue 69,205 64,014 Cost of Sales (43,207) 62.4% (40,435) 63.2% Gross Profit 25,998 37.6% 23,579 36.8% Other Income 2,659 3.8% 2,295 3.6% Selling and distribution expenses (25,964) 37.5% (19,634)
Slide 8: Financial Performance – Summary Balance Sheet
FINANCIAL PERFORMANCE – SUMMARY Balance Sheet NZ#039;000's year ended 31 March 2017 2016 ASSETS Current Assets Inventories 18,718 16,499 Trade and other receivables 19,362 17,475 Cash and cash equivalents 15,980 28,055 Current income tax asset - 26 Total current assets 54,060 62,055 Non-current Assets
Slide 9: Financial Performance – Summary Cashflow
FINANCIAL PERFORMANCE – SUMMARY Cashflow NZ#039;000's year ended 31 March 2017 2016 Net cash used in operating activities (19,062) (13,942) Net cash used in investing activities (1,598) (1,181) Net cash generated from financing activities 9,042 36,705 Net increase in cash (11,618) 21,582 Impact of fore
Slide 10: Advanced Clinical Study Program
ADVANCED CLINICAL STUDY PROGRAM • 12 studies across the AFT portfolio • 1300+ patients • 5 countries - Australia, New Zealand, Russia, United Kingdom, United States • Significant Clinical Trials for Maxigesic oral and IV dose forms are mainly completed with studies • Completing Maxigesic IV pivotal
Slide 11: Maxigesic Update
MAXIGESIC UPDATE Nordics – launch pending Eastern Europe and Balkans – launch pending UK – launched BE/LX & FR– launch pending Italy – successful launch and ES/PT – launch pending IE – launch pending sales increasing significantly Kuwait and Iraq launch pending UAE – sales doubled in second year of
Slide 12: Maxigesic Tablet Sales Progress to Date
MAXIGESIC TABLET SALES PROGRESS TO DATE 80,000,000 70,000,000 60,000,000 50,000,000 40,000,000 30,000,000 20,000,000 10,000,000 - FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 All Ma rke ts Maxigesic Tablets Sold [Mill] Per Year [FY17 sales estimates based upon actual first 5 months, current orders and li
Slide 13: Example of Maxigesic Licensee Progress to Date
EXAMPLE OF MAXIGESIC LICENCEE PROGRESS TO DATE – tablet sales per month 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 - Ma xig e s ic Ta ble ts Lin e a r (Ma xig e s ic Ta b le ts ) Investor Presentation 12 May 2017
Slide 14: Maxigesic: Going Forwards
MAXIGESIC: GOING FORWARDS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 110. Some additional larger countries to be added – North America and larger EU Numerous Maxigesic registrations underway which are re
Slide 15: NasoSURF Nebuliser: Going Forwards
NASOSURF NEBULISER: Going Forwards A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description chronic sinusitis The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not approved for delivery of spec
Slide 16: Summary of Medium Term Plans
SUMMARY OF MEDIUM TERM PLANS Phased launches of Maxigesic in over 100 countries including North America Add additional Maxigesic dose forms to the initial launches to extend sales Further licensing agreements for Maxigesic and Maxigesic IV in larger markets including North America and larger EU coun